Events Partner Content Hit the JAK-pot in global race to treat COVID-19 Hit the JAK-pot in global race to treat COVID-19
News FDA starts review of BMS's 'celmod' for multiple myeloma Bristol Myers Squibb could be months away from bringing the first 'celmod' to market, as the FDA starts a review of iberdomide for multiple myeloma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
